Minneapolis, MN, United States of America

Paul Pentel

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignees: Antidote Therapeutics, Inc., Blink Biomedical, Hennepin Healthcare Research Institute. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Pentel. Retrieved from https://idiyas.com/inventor/paul-pentel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paul Pentel: Innovator in Nicotine Addiction Treatment

Introduction

Paul Pentel is a notable inventor based in Minneapolis, MN (US). He has made significant contributions to the field of nicotine addiction treatment through his innovative research and development. His work focuses on creating solutions that aid in smoking cessation and address nicotine-related health issues.

Latest Patents

Pentel holds a patent for nicotine-binding antibodies. This patent describes novel nicotine-binding antibodies and methods for using them to treat nicotine addiction, facilitate smoking cessation, and address nicotine overdose or poisoning. His innovative approach has the potential to change the landscape of nicotine addiction treatment.

Career Highlights

Throughout his career, Paul Pentel has worked with various companies, including Antidote Therapeutics, Inc. and Blink Biomedical. His experience in these organizations has allowed him to develop and refine his ideas, contributing to advancements in medical treatments related to nicotine.

Collaborations

Pentel has collaborated with notable individuals in his field, including Matthew W. Kalnik and Thomas Thisted. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Paul Pentel's work in developing nicotine-binding antibodies showcases his commitment to addressing nicotine addiction and improving public health. His contributions to this field are invaluable and highlight the importance of innovation in medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…